Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132370 | 0.87 | FFAR4 (0.61) | FFAR4FFAR1AKR1B1GPR84PPARG | |
| SCHEMBL76196 | 0.83 | FFAR4 (0.55) | FFAR4FFAR1AKR1B1GPR84PPARG | |
| SCHEMBL28948898 | 0.83 | GPR84 (0.52) | FFAR4FFAR1AKR1B1GPR84PPARG | |
| SCHEMBL9164196 | 0.83 | GPR84 (0.52) | FFAR4FFAR1AKR1B1GPR84PPARG | |
| SCHEMBL28037052 | 0.83 | FFAR4 (0.55) | FFAR4FFAR1AKR1B1GPR84PPARG | |
| SCHEMBL31361791 | 0.83 | GPR84 (0.52) | FFAR4FFAR1AKR1B1GPR84PPARG | |
| SCHEMBL2458473 | 0.83 | FFAR4 (0.55) | FFAR4FFAR1AKR1B1GPR84PPARG | |
| SCHEMBL6460926 | 0.81 | FFAR4 (0.53) | FFAR4FFAR1AKR1B1GPR84PPARG | |
| SCHEMBL4539300 | 0.80 | GPR84 (0.49) | FFAR4FFAR1AKR1B1GPR84PPARG | |
| SCHEMBL18211189 | 0.80 | FFAR4 (0.61) | FFAR4FFAR1AKR1B1GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1237968-C | Methods of inhibiting proliferation and inducing apoptosis in cancer cells | UNIV CREIGHTON (US) | 2006-01-25 | — | — | CN | disclosed |
| US-20040053962-A1 | Methods for inhibiting proliferation and inducing apoptosis in cancer cells | CREIGHTON UNIVERSITY | 2004-03-18 | — | — | US | disclosed |
| CN-1429111-A | Methods of inhibiting proliferation and inducing apoptosis in cancer cells | CREIGHTON UNIV (US) | 2003-07-09 | — | — | CN | disclosed |
| EP-0599943-A1 | LEUKOTRIENE RECEPTOR ANTAGONIST-ANTIHISTAMINE COMPLEX | ALLERGAN, INC. (US) | 1994-06-08 | — | — | EP | disclosed |
| US-5276044-A | For topical application having enhanced effectiveness and decreased irritancy | ALLERGAN, INC. (US) | 1994-01-04 | — | — | US | disclosed |
| WO-1993003723-A1 | LEUKOTRIENE RECEPTOR ANTAGONIST-ANTIHISTAMINE COMPLEX | ALLERGAN, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053962-A1 | Methods for inhibiting proliferation and inducing apoptosis in cancer cells | LTB4R, LTB4R2, ALOX5 | FFAR4 48/4885FFAR1 81/4885AKR1B1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.